Welcome to the latest edition of the  BioLines Weekender... in these unprecedented, uncertain and unnerving times in which we find ourselves.    
Despite that, there is a ray of hope...being provided by this industry.  While it will take time, our Members are diligently working on antiviral therapies and vaccines to combat the virus. And earlier this week Hackensack Meridian Health received FDA approval to begin using the COVID-19 test developed in its Center for Discovery and Innovation. HMH officials said the test will dramatically reduce the time it takes for diagnosing COVID-19, calling it a major advance that will benefit Patients, create a more effective triage system in hospitals and potentially better control the spread of disease. 
Through the innovation of our industry, working together with the FDA, BioNJ is optimistic that an effective treatment can be identified to address this pandemic.
As we navigate these uncharted waters together, we recommend that our Members refer to BioNJ's Combating COVID-19 Toolbox for useful guidelines, policies and information on how employers are addressing employee concerns and safety needs. Our toolbox is being updated daily as we learn of new tools and data. Please send your best practices to RBromberg@BioNJ.org for us to share with our community. Let's learn from one another. Thank you.
Wishing everyone the very best of health.

Because Patients Can't Wait®,
The BioNJ Team

BioNJ Calendar

BioNJ's 10th Annual BioPartnering Conference
Somerset, NJ
Register today!
May 13, 2020
Putting Patients First: The Value of Medical Innovation

Medical innovation enables longer and better quality lives and, in turn, reduces the costs of health care. Share with our community how your medical innovation is improving lives and impacting health care costs. Send us your Patient and related stories to BioNJ@BioNJ.org. Plus, click here for valuable tools and resources on the Value of Medical Innovation.

U.S. President Donald Trump signed an emergency spending bill for $8.3 billion to ramp up the nation's response to the coronavirus, providing funds for state and local officials to combat the spread of infections as the number of cases grows in the United States.  The funding measure includes over $3 billion for research and development of vaccines, test kits and medical treatments, $2.2 billion to aid public health activities on prevention, preparedness and response and $1.25 billion to help international efforts aimed at reining in the virus.

Gunjan Doshi, the Chair of the State's  Commission on Science, Innovation and Technology (CSIT), was thrilled when he heard the news. Gov. Murphy included a substantial increase in funding for CSIT in his budget proposal.  Murphy, who has pushed STEM and innovation since the campaign trail, is proposing to increase funding allocated to CSIT to $3 million, up from $1 million last year. In August 2018, Murphy signed legislation re-establishing the former New Jersey Commission on Science and Technology as the New Jersey Commission on Science, Innovation and Technology. The commission is tasked with leading the way in promoting the state as a home for academic and technological research, development and commercialization.

NJ Pride

These small (15 - 40 employees), medium (50 - 249 employees) and large (more than 250 employees) honorees are decided based upon their participation with the Best Places to Work survey, from fellow BridgeTower Media firm Best Companies Group. The program confidentially collects data, allowing workers to comfortably share feedback about their employers, and for those companies to learn from and act on what they learn. 
Congratulations to this year's winners, including BioNJ Members:  GENEWIZ , Genmab Langan Engineering and Environmental Services Inc.Lowenstein Sandler LLPPorzio, Bromberg & Newman PC, RSM US LLP and The Execu|Search Group.

BioNJ in the News

A blog by Debbie Hart, President and CEO, BioNJ

As a leader within the New Jersey life sciences, ensuring that patients have affordable access to prescription medicines is a leading priority for my organization and the scientists and researchers we represent. We strongly believe that policymakers at both the state and federal levels should take responsible steps to help reduce what patients pay out of pocket for their medicines.

Congratulations to BioNJ President and CEO Debbie Hart for making ROI-NJ's Influencers Power List 2020 for Associations. 

Debbie Hart
President and CEO, BioNJ
"Debbie remains a force statewide -- and globally -- for a life sciences/bio industry that is still one of the most impactful in the State."

NJ Company News

The U.S. Food and Drug Administration approved East Hanover-based BioNJ-Member Novartis' Isturisa (osilodrostat) oral tablets for adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Cushing's disease is a rare disease in which the adrenal glands make too much of the cortisol hormone. Isturisa is the first FDA-approved drug to directly address this cortisol overproduction by blocking the enzyme known as 11-beta-hydroxylase and preventing cortisol synthesis. 

East Hanover-based BioNJ Member Novartis announced the European & Developing Countries Clinical Trials Partnership (EDCTP) awarded a new grant to the new PAMAfrica research consortium led by Medicines for Malaria Venture (MMV). The consortium will support the development of new treatments for malaria in the most-at-risk populations, including babies, patients with severe malaria, and those with drug-resistant infections. The EDCTP grant of €21.9 million is to be matched by funding from MMV, Novartis and partners.

BioNJ Member RenovaCare Inc. said it will establish a new corporate headquarters in Roseland and laboratory facilities in Berlin, Germany to advance the development of its patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues. "We are enthusiastic about our new corporate headquarters in New Jersey and tapping into its deep scientific and biomedical talent along with the area's strong financial investment community," said RenovaCare Chief Executive Officer Alan Rubino.

Bedminster-based BioNJ Member  Matinas BioPharma Holdings, Inc. announced that it has initiated the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa® in patients with elevated triglycerides (150-499 mg/dL). The ENHANCE-IT study will assess MAT9001's effectiveness in reducing triglyceride levels and other important lipid markers, as well as gather important data on bioavailability and blood levels of eicosapentaenoic acid (EPA) and other omega-3 fatty acids. 

Jersey City-based BioNJ Member SCYNEXIS, Inc. announced that data from a preclinical study of oral ibrexafungerp in combination with azoles against Aspergillus species isolated from lung transplant recipients showed synergistic activity of ibrexafungerp in combination with azoles against Aspergillus isolates. Ibrexafungerp is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections, including invasive aspergillosis.

Cranbury-based BioNJ Member  Outlook Therapeutics, Inc.  announced that it has received  U.S. Food and Drug Administration  (FDA) tentative approval of the Tradename for ONS-5010 as LYTENAVA™ (bevacizumab-vikg). The Tradename is conditionally approved by FDA and will be subject to further review at the time of the company's planned filing of a new biologics license application (BLA) with the FDA for LYTENAVA™ (bevacizumab-vikg) in 2021. 

Pennington-based BioNJ Member  OncoSec Medical Incorporated announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of $850,000 from the Australian Tax Office. The Australian government established this tax incentive program to stimulate local industry investment in R&D by offering businesses tax offsets for eligible R&D expenditures made in Australia. OncoSec previously established a subsidiary in Australia and is conducting a portion of both of its TAVO™ KEYNOTE clinical trials as well as other R&D activities in the region.

Bridgewater-based BioNJ Member  Insmed Incorporated announced the granting of inducement awards to three new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the company. In connection with the commencement of their employment, the employees received options on March 2, 2020 to purchase an aggregate 3,720 shares of Insmed common stock at an exercise price of $26.10 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

Hampton-based BioNJ Member  Celldex Therapeutics, Inc.  announced that the company will receive a  $1.7 million  payment related to an existing 2013 agreement with  Rockefeller University  under which Celldex performed manufacturing and development services for Rockefeller University's portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including two clinical-stage candidates 3BNC117 and 10-1074. These investigational agents have potential for use in HIV long-acting therapies for treatment and prevention, as well as cure strategies. 

Princeton-based BioNJ Member Bristol-Myers Squibb announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib. Approval for this indication has been granted under accelerated approval based on overall response rate and duration of response seen in the Opdivo + Yervoy cohort of the Phase 1/2 CheckMate -040 trial.

Princeton-based BioNJ Member Bristol-Myers Squibb and Voluntis announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients. Leveraging Theraxium Oncology, Voluntis' core platform for digital therapeutics in oncology, the collaboration will evaluate potential solutions that will support management of patient symptoms and remote monitoring by health care providers. The goal is that the digital therapeutic, once researched and developed, would provide patients access to a mobile app that would support treatment and track symptoms.

Bridgewater-based BioNJ Member  Eli Lilly and Company  and AbCellera announced they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and  Lilly 's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies. 

Bridgewater-based BioNJ Member  Eli Lilly and Company and Boehringer Ingelheim announced that The  U.S.  Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance ®  (empagliflozin) to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease . This Fast Track designation for Jardiance underscores the urgent need for additional treatment options for the over 30 million Americans living with chronic kidney disease, many of whom are at risk of progressing to end-stage kidney disease.

Bridgewater-based BioNJ Member  Eli Lilly and Company  and BioNJ Member Pfizer (with offices in Peapack) announced that the  U.S. Food and Drug Administration  (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics. Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF) inhibitors.

Bridgewater-based BioNJ Member  Eli Lilly and Company  announced that a  U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee  (ODAC) voted 6-5 that CYRAMZA ®  (ramucirumab) plus erlotinib demonstrated a favorable benefit/risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer (NSCLC), based on the results of the positive Phase 3 RELAY study. The ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License Application (sBLA) currently under review by the FDA.

Ramsey-based BioNJ Member  ADMA Biologics, Inc. announced that it has received another Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application related to its intellectual property portfolio encompassing immunoglobulin plasma pool compositions used in the manufacturing of ASCENIV™.  ADMA is the exclusive owner of intellectual property encompassing certain immunotherapeutic, immunoglobulin (IG & IVIG) compositions for the prevention and treatment of a wide variety of respiratory infections, including certain strains of coronavirus.

Raritan-based The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. JNJ-6372 is an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody that targets activating and resistant EGFR and MET mutations and amplifications.

Raritan-based The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Medicines Agency (EMA) has granted both PRIME (PRIority MEdicinesand Advanced Therapy Medicinal Product (ATMP) designations to the company's adeno-associated virus (AAV)-RPGR gene therapy product for the treatment of inherited retinal disease X-linked retinitis pigmentosa (XLRP). PRIME is awarded to increase interactions, optimize development plans and accelerate innovative treatments where there is unmet medical need. 

Kenilworth-based BioNJ Member  Merck & Co. announced that the Phase 3 KEYNOTE-204 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) met one of its dual primary endpoints of progression-free survival (PFS). Based on an interim analysis conducted by an independent Data Monitoring Committee (DMC), KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in PFS compared with brentuximab vedotin (BV) in this patient population. 

Kenilworth-based BioNJ Member  Merck & Co. and the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, announced the publication of research on the discovery of a novel class of candidate antimalarial agents that block multiple stages of the lifecycle of the parasite that causes the disease. Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum, the predominant cause of the most severe form of the disease. 

In a recent study conducted by KMK Consulting, Inc., covering Innovation & Customer Value in the Breast Cancer market, Genentech (a member of the Roche Group) was ranked as the top company delivering superior customer value and sales force engagement, as well as delivering therapeutic innovation in this space. The research was conducted in  February 2020 , using KMK's Rapid Pulse Survey platform. BioNJ Members Pfizer and Merck & Co. rounded out the top three organizations that were deemed best poised for delivering future therapeutic innovations in the treatment of this disease.   

The number of confirmed coronavirus cases worldwide hit over 100,000, raising concerns that the outbreak has reached a new stage and could continue its global spread. It is understandable that this is a novel strain of coronavirus that has suddenly appeared, and various physical characteristics of the virus itself make it difficult to develop a timely treatment. It may take a year or more to develop a vaccine, and at that time it may no longer be effective due to mutations of the virus. North Brunswick-based BioNJ Member BioAegis Therapeutics co-founder, Steve Cordovano, shares his perspective on why health organizations are so ill-prepared to deal with infectious-disease outbreaks.

Warren-based Bellerophon Therapeutics, Inc.  announced the successful completion of its End-of-Phase 2 Meetings with the  U.S. Food and Drug Administration  (FDA) for INOpulse ®  for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF). The company, in consultation with the FDA, has finalized the key elements of its planned pivotal Phase 3 study, including the use of moderate to vigorous physical activity (MVPA) as the primary endpoint for approval, the patient population of pulmonary fibrosis subjects at risk of PH, as well as the dose of iNO45 (45 mcg/kg IBW/hr). 

Elmwood Park-based  BioReference Laboratories, Inc. announced it will offer a test for the novel coronavirus (2019-nCoV), a contagious virus that causes respiratory infection and has shown evidence of human-to-human transmission. BioReference is expecting to receive specimens for testing, and begin to provide testing next week. With an extensive network of patient service centers and a national logistic network, BioReference will provide expanded access to a COVID-19 testing across  the United States .

Bedminster-based  Mallinckrodt plc  announced publication of findings from a prospective, open-label pilot study to assess the efficacy and safety of Acthar ®  Gel (repository corticotropin injection) in patients with immunoglobulin A nephropathy (IgAN) at high risk of chronic kidney disease progression. The  study  was published in  Kidney International Reports IgAN, also known as Berger's disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues.

Florham Park-based Shionogi & Co., Ltd. announced FETROJA® (cefiderocol) is now available in the U.S. for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Escherichia coli (E. coli), Klebsiella pneumoniae (K. pneumoniae), Proteus mirabilis (P. mirabilis), Pseudomonas aeruginosa (P. aeruginosa), and Enterobacter cloacae (E. cloacae) complex

Princeton-based PDS Biotechnology Corporation announced commencement of work under an Amended and Restated Material Transfer Agreement with Farmacore Biotechnology, experts in infectious diseases, to develop a novel tuberculosis (TB) immunotherapy based on Farmacore's proprietary TB antigens and PDS Bio's Versamune® platform technology.  The prior Material Transfer Agreement under which preliminary work commenced was Amended and Restated in December 2019 due to promising early pre-clinical results and to progress this next phase of development.

Bridgewater-based  Menlo Therapeutics Inc. announced the completion of its merger with  Foamix Pharmaceuticals Ltd. following the satisfaction of all closing conditions required by the merger agreement.  Upon completion of the merger, Foamix became a wholly-owned subsidiary of Menlo. "This is an exciting day as we take a significant step toward becoming a broad dermatology franchise. The combined company already has an approved, commercial-stage product, AMZEEQ, and several late-stage product candidates with several meaningful near-term catalysts," said David Domzalski, who became the Chief Executive Officer of Menlo upon the closing of the merger.

Hackensack-based  BrainStorm Cell Therapeutics Inc.  announced that it has entered into a definitive agreement with  Abbhi Investments, LLC  in connection with a privately negotiated sale of common stock and a warrant to purchase common stock (collectively, the "securities"). BrainStorm intends to use the proceeds from this transaction to fund its operations, which includes, but is not limited to advancing the company's clinical programs, commercial production of the investigational therapeutic NurOwn® (whether for ALS or other indications), regulatory, pre-marketing and commercialization preparation activities of NurOwn® for ALS, working capital and general corporate purposes.

Eatontown-based Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals announced the signing of an exclusive U.S. license agreement to commercialise Ryaltris™ (olopatadine hydrochloride and mometasone furoate nasal spray), an investigational fixed-dose combination nasal spray for the treatment of seasonal allergic rhinitis (SAR). Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris™ by the US Food and Drug Administration (FDA). Hikma will be responsible for the commercialisation of Ryaltris™ in the U.S. following approval.

DBV Technologies, with offices in  Summit, announced that the underwriters for its previously announced global offering have partially exercised their option to purchase 338,687 additional ordinary shares in the form of 677,374 American Depositary Shares ("ADSs"), at an offering price of $10.25 per ADS, before deducting commissions and estimated offering expenses (the "Option"). The company plans to use the net proceeds from the global offering, together with its existing cash and cash equivalents, primarily to prepare for the commercialization of Viaskin Peanut, including marketing efforts related to launch in the second half of 2020, if approved.

Lawrenceville-based Asana BioSciences announced positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008. The Phase 1b double-blind, vehicle-controlled, dose escalation study randomized 25 adult patients with atopic dermatitis and a pruritus score of ≥7 using the Numerical Rating Scale (NRS) at baseline. Patients were randomized 3:1 receiving either ASN008 gel or vehicle gel applied topically either once or twice daily for 14 days.

Princeton-based WIRB-Copernicus IRB announced a new program to support initiation of protocols associated with mitigating the global spread of coronavirus. WIRB-Copernicus IRB will give prioritized review to clinical trial protocols for COVID-19 (coronavirus) prophylactic or therapeutic vaccines and therapeutic agents, conducted under an investigational new drug (IND) application. WIRB-Copernicus IRB will also waive the initial protocol review fees for that research. To qualify for this new program, the COVID-19 protocol must be submitted before Sept. 1, 2020.

People in the News

Cranbury-based BioNJ Member Rafael Pharmaceuticals, Inc.  announced the appointment of Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer. The newly created position is indicative of the company's continued commitment and dedication to adhere to global governmental regulations and standards, surrounding its lead compound CPI-613® (devimistat). Dr. Sehgal has more than 25 years of experience working with both multinational and small biotechnology companies. Most recently, he served as the Senior Vice President of Regulatory Affairs and Conformance at Celularity,

Morris Plains-based BioNJ Member  Immunomedics, Inc.  announced the appointment of Robert W. Azelby to the Company's board of directors. Mr. Azelby is a biotech industry veteran with 28 years of biopharmaceutical experience with a large emphasis on commercialization. Mr. Azelby was recently the president and chief executive officer, and a member of the board of directors, of Alder BioPharmaceuticals, Inc. Previously, Mr. Azelby served as Executive Vice President, Chief Commercial Officer of Juno Therapeutics, Inc. where he was responsible for the development and implementation of Juno's CAR-T commercial strategy and helped guide the organization through rapid growth and ultimately to a $9 billion acquisition by Celgene Corporation.

Bridgewater-based  Amneal Pharmaceuticals Inc.  announced Tasos Konidaris was appointed as Senior Vice President, Chief Financial Officer. Mr. Konidaris brings more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics and data industries. Mr. Konidaris most recently served as Chief Financial Officer and as a board member of Alcresta Therapeutics Inc. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria Inc.

Institution and Education News

The New Jersey Innovation Institute's (NJII)  Biopharma division is pleased to announce the formation of their advisory committee which includes experts from across the industry.  The committee will meet quarterly and provide strategic direction to the division as well as help identify emerging opportunities and challenges in the area of regenerative medicine. The chairwoman of the committee will be Dr. Joanne Beck, Chief Operating Officer of Boston Pharmaceuticals. 

It is evident that t he cell and gene therapy sectors are growing faster than the field of available talent, pressuring start-ups and established players alike.  That was the key driver for the Talent Development Ideation Meeting, held on NJIT's campus . NJII's Biotechnology & Pharmaceutical Innovation iLab hosted more than a dozen leading biopharma executives from business, government and academia in a roundtable discussion to strategize ways of attracting, training and retaining talent to the industry. Dr. Peter Marks, the director of the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA), served as the event's keynote speaker.

Rutgers engineers have created a tabletop device that combines a robot, artificial intelligence and near-infrared and ultrasound imaging to draw blood or insert catheters to deliver fluids and drugs.  Their most recent research results,  published in the journal Nature Machine Intelligence , suggest that autonomous systems like the image-guided robotic device could outperform people on some complex medical tasks. Medical robots could reduce injuries and improve the efficiency and outcomes of procedures, as well as carry out tasks with minimal supervision when resources are limited. 

Hackensack Meridian Health has gotten  U.S. Food & Drug Administration approval to begin using the COVID-19 test it developed in its  Center for Discovery and InnovationHMH officials said the test will dramatically reduce the time it takes for diagnosing COVID-19, calling it a major advance that will benefit patients, create a more effective triage system in hospitals and potentially better control the spread of disease.  HMH began using the test at  Hackensack University Medical Center The new diagnostic tool will help the health network to quarantine and treat patients suspected of having COVID-19 more rapidly or, in the case of a negative result, spare the patient unnecessary time in the hospital.

Funding News

Pursuant to Executive Order 103 (Murphy 2020) ("EO 103") in response to increasing numbers of employers encouraging employees to work from home in response to the COVID-19 pandemic, the New Jersey Economic Development Authority (NJEDA) is waiving certain specific requirements related to employee presence in the office for the recipients of awards under employment-based incentive programs. 

The  New Jersey Economic Development Authority (NJEDA)  announced that it will host a series of  NJEDA Roadshow  events, designed to raise awareness of the Authority's resources for municipalities, communities and businesses of all sizes across all sectors. The events, which will be held in all 21 counties, are being created in coordination with economic development partners at the county and municipal levels. The NJEDA is committed to making New Jersey a national model for inclusive and sustainable economic development by focusing on key strategies to help build strong and dynamic communities, create good jobs for New Jersey residents, and provide pathways to a stronger and fairer economy.

Special Programs from Our Partners for BioNJ Members

March 21, 2020 | Union

STEM professionals will present highlights on their careers and hot topics in science, technology, engineering and math with a Q&A session following. Geared for all audiences.  Registration is required. All seminars are FREE for NJAS members. Students can attend for free with a student ID. A nominal donation of $5 for the general public. Click here for more information and to register.

March 31, 2020 | North Brunswick

Hear insight into alternative sources of funding to advance life sciences companies in New Jersey.  The panel will focus on securing funding from non-traditional sources. Topics include: How will the next generation of drugs, diagnostics and devices be funded? What new models are there that might change the paradigm? Is there a better way to fund early and emerging commercial medical research? There is no cost to attend, but registration is requested prior to the event. To register, visit March2020AlternativeFundingForLifeSciences.eventbrite.com

April 7, 2020 | Morristown

Students 2 Science is delighted to invite you to S2S: The Salon, a community gathering in celebration of S2S' 10-year anniversary. It will be a wonderful event with key influencers in the State of New Jersey representing both public and private sectors, including corporate leaders, educators, administrators and policy officials. A panel discussion, led by BioNJ President and CEO Debbie Hart will engage participants in a dialogue on the urgent and important topics of equity and diversity in STEM education: "How Do We Encourage a Ready and Diversified Workforce in STEM?" For more information on tickets and sponsorship contact S2S@students2science.org. 

April 26-28, 2020 | Philadelphia

This interactive workshop is designed as an introductory course covering all aspects of drug discovery for neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Degeneration and Multiple Sclerosis. Delegates are drawn from academia, industry, associations/societies, government and media. The event attracts about 150-170 attendees allowing for a higher degree of interactivity and networking. Contact RBromberg@BioNJ.org for the BioNJ Member 20% discount registration code.

June 8-11, 2020 | San Diego

The BIO International Convention is hosted by the  Biotechnology Innovation Organization  (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The BIO International Convention offers a range of opportunities to increase your brand exposure and connect with a global audience of 17,000+ attendees from 65+ countries. 

BioNJ Member Services Provider Directory

BioNJ recognizes the vital role that our Service Provider Members play in the growth of New Jersey's robust life sciences ecosystem. For this reason, we are delighted to remind our community about BioNJ's Member Service Provider Directory, a categorical listing of BioNJ Members by service sector. By working with fellow BioNJ Member organizations, you are not only supporting our community, but benefiting from a wide variety of high quality organizations.  To learn how you can become a Member and be featured on this resource tool, please contact Kim Minton at KMinton@BioNJ.org, or 609-890-3185. Find providers in these categories:

The NJBAC is a state agency offering free and confidential assistance to help your business grow. As a "one-stop shop," NJBAC can help businesses of all sizes and types manage the state's regulatory processes, boost exports, gain access to financial resources where applicable and tackle other obstacles along the way. You can download the NJBAC guide by clicking here or contact their business advocates at 1-800 JERSEY 7.

Please contact BioNJ at BioNJ@BioNJ.org or call 609-890-3185 
with any questions.